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Abstract
Background: Prostate cancer is the second leading cause of cancer mortality in American men. Although serum PSA 
testing is widely used for early detection, more specific prognostic tests are needed to guide treatment decisions. 
Recently, the enumeration of circulating prostate epithelial cells has been shown to correlate with disease recurrence 
and metastasis following definitive treatment. The purpose of our study was to investigate an immunomagnetic 
fractionation procedure to enrich circulating prostate tumor cells (CTCs) from peripheral blood specimens, and to 
apply amplified molecular assays for the detection of prostate-specific markers (PSA, PCA3 and TMPRSS2:ERG gene 
fusion mRNAs).
Results: As few as five prostate cancer cells were detected per 5 mL of whole blood in model system experiments 
using anti-EpCAM magnetic particles alone or in combination with anti-PSMA magnetic particles. In our experiments, 
anti-EpCAM magnetic particles alone exhibited equivalent or better analytical performance with patient samples 
compared to a combination of anti-EpCAM + anti-PSMA magnetic particles. Up to 39% of men with advanced prostate 
cancer tested positive with one or more of the molecular assays tested, whereas control samples from men with 
benign prostate hyperplasia gave consistently negative results as expected. Interestingly, for the vast majority of men 
who tested positive for PSA mRNA following CTC enrichment, their matched plasma samples also tested positive, 
although CTC enrichment gave higher overall mRNA copy numbers.
Conclusion: CTCs were successfully enriched and detected in men with advanced prostate cancer using an 
immunomagnetic enrichment procedure coupled with amplified molecular assays for PSA, PCA3, and TMPRSS2:ERG 
gene fusion mRNAs. Our results indicate that men who test positive following CTC enrichment also exhibit higher 
detectable levels of non-cellular, circulating prostate-specific mRNAs.
Introduction
Serum PSA testing is widely used for prostate cancer
screening, however more specific tests are needed to
guide treatment decisions following definitive biopsy.
Furthermore, tests are needed to detect disease recur-
rence following radiation and/or surgical intervention,
especially considering the increasing rate of targeted
therapies for patients who do not have their prostates
surgically removed. Considerable effort has been directed
toward the development of methods for detecting circu-
lating prostate tumor cells (CTCs) as an early indicator of
distal disease progression. Early studies focused on RT-
PCR methods for detection of prostate-specific mRNAs
in whole blood [1,2]. These mRNAs were originally pre-
sumed to be a surrogate measure of the presence of
CTCs, however conflicting results have been reported
regarding the clinical utility of this approach [3,4]. More
recently, investigators have focused on methods for
detecting and enumerating CTCs directly [5], and one
commercial assay is now available [6]. Nonetheless, the
full clinical significance of CTCs remains somewhat con-
troversial, although increasing numbers of clinical studies
have supported this approach [7].
Circulating tumor cells have been isolated and charac-
terized from the blood of cancer patients by a variety of
methods [8]. The enumeration of CTCs in a population of
advanced stage prostate cancer patients has been corre-
lated with poor prognosis [9-11]. Furthermore, enumera-
tion of CTCs following surgical intervention showed a
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greater correlation with survival than serum PSA moni-
toring [7].
Here we describe an immunomagnetic method of CTC
enrichment that can be used as a convenient preanalytical
step for detecting prostate-specific mRNAs by using
transcription-mediated amplified (TMA) molecular
assays. The method employed a standardized, magnetic
particle-based capture system that is compatible with the
automated TMA assay formats. Magnetic particles were
derivatized with antibodies targeting either prostate spe-
cific membrane antigen (PSMA) or the epithelial cell
adhesion molecule (EpCAM). PSMA, a type II mem-
brane-bound glycoprotein, is mainly expressed in pros-
tate tissue, although it has also been found in
neovasculature [12,13]. Because its expression is elevated
in prostate cancer tissues [14], we chose it to be an anti-
gen for the immunomagnetic enrichment procedure
described herein. We tested magnetic particles deriva-
tized either with anti-EpCAM alone or with a combina-
tion of anti-EpCAM plus anti-PSMA to investigate
potential synergy in CTC enrichment experiments.
Prostate-cancer-specific molecular markers have been
reviewed recently and it is evident that the field will con-
tinue to evolve as new recurrent molecular markers are
elucidated [15-17]. For the present work, we chose PCA3
mRNA and TMPRSS2:ERG gene fusion mRNA, since
diagnostic utility has already been demonstrated for these
markers in urine specimens [18,19]. We hypothesized
that the immunomagnetic enrichment method described
herein could be used together with PCA3 and
TMPRSS2:ERG assays to specifically detect CTCs in
advanced prostate cancer. TMPRSS2:ERG gene fusions
have been associated with aggressive prostate cancer in a
transgenic mouse model [20], detected in distant metas-
tasis [21] and also linked with aggressive prostate cancer
phenotypes in humans [22,23]. Moreover, it was demon-
strated recently that a portion of TMPRSS2:ERG positive
tumors did not respond to androgen ablation therapy
[24]. We also included an amplified molecular assay for
PSA mRNA with CTC enrichment as a marker for pros-
tate-derived cells. The current study describes prelimi-
nary clinical data in support of feasibility for detecting
the above molecular markers in CTCs and in most cases
also in matched plasma specimens. Future studies will be
needed to assess the clinical utility of the described assay
system.
Materials and methods
Cell lines
The C4-2 prostate cancer cell line [25] was a gift from
Leland Chung, Ph.D. (Emory University). LNCaP cells
[26] were obtained from the American Type Culture Col-
lection (ATCC; Manassas, VA). GFP-LNCaP cells were
kindly provided by Dr. Srivastava, Center for Prostate
Disease Research (Rockville, MD). All cell lines were
grown under standard culture conditions in RPMI 1640
medium supplemented with 10% fetal bovine serum
(ATCC), and with G418 (0.5 mg/mL; Invitrogen, Carls-
bad, CA) for GFP-LNCaP cells.
Preparation of prostate cancer cells for use in model system 
of immunomagnetic cell isolation
GFP-LNCaP cells were treated by mild trypsinization
(Trypsin/EDTA, Invitrogen, Carlsbad, CA) from one 25
mm2 dish (BD, Franklin Lakes, NJ) and harvested by sedi-
mentation (500 g, 5 min, room temperature). The cell pel-
let was resuspended in PBS (dPBS, Invitrogen, Carlsbad,
CA). C4-2 cells were harvested as described above for
GFP-LNCaP cells. Individual cells (n = 5, 10, 25) were
aspirated with a micromanipulator pipette system
(TransferMan NK, Eppendorf and Leica DMIRB inverted
microscope) and added to normal donor blood treated
with EDTA to prevent coagulation. Freshly harvested
LNCaP cells were transferred to a 10 cm Petri dish con-
taining RPMI 1640 medium at room-temperature. Indi-
v i d u a l  c e l l s  w e r e  a s p i r a t e d  m a n u a l l y  w i t h  a  s t a n d a r d
laboratory pipette under low microscopic magnification
(Olympus CK2 equipped with 10× lens) and added to
EDTA-treated normal donor blood. Immunomagnetic
cell isolation was carried out as described in more detail
below. Briefly, for each of the cell lines tested individually
in the model system, freshly resuspended cultured cells
were added to 1 mL EDTA blood (approximately 100
cells) and incubated with 10 uL anti-EpCAM coated mag-
netic particles (Invitrogen, Carlsbad, CA) for 20 min at
room temperature. Magnetic-bound fractions were
washed three times, as described below, and then the
washed particles were subjected to fluorescence micros-
copy as described below.
Specimen processing
Specimen processing included CTC enrichment and cell
lysis. For specimens that contained C4-2 cells, specimen
processing was performed at the University of Washing-
ton (Seattle, WA) and the processed specimens were
shipped to Gen-Probe Incorporated (San Diego, CA) on
dry-ice for further testing. Processing of specimens that
contained LNCaP cells or GFP-LNCaP cells was done at
Gen-Probe Incorporated.
Microscopy
For visualization experiments of magnetically enriched
cells, about 20 μL Mowiol mounting medium [27] was
added to the washed magnetic particles. The resulting
suspension was spotted onto a glass slide and covered
with a round glass cover slip (18 mm diameter) to prevent
drying. The mounted cells were visualized with a fluores-
cence microscope with 10× and 40× lenses (Axio ImagerJost et al. Molecular Cancer 2010, 9:174
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Z1, Zeiss, Thornwood, NY). Pictures were taken with an
attached CCD camera (Metasystems, Waltham, MA).
GFP-LNCaP cells in EDTA-treated blood were visualized
after spreading a thin film onto a glass slide without a
cover slip to prevent cellular rupture.
Patient Selection
Specimen collection was carried out at the University of
Washington under IRB approved protocols that included
written informed consent from each of the subjects. This
study included consecutive patients who consented and
fell within the inclusion and exclusion guidelines. In total,
sixty-five men diagnosed with prostate cancer partici-
pated in this study: thirty-five men who had been diag-
nosed with advanced-stage prostate cancer by bone scan
(hereafter referred to as advanced PCa) and twenty-nine
who had been diagnosed as early-stage cancer patients by
biopsy following a serum PSA determination and digital
rectal exam (hereafter termed pre-radical retropubic
prostatectomy (pre-RP)). Moreover, five men diagnosed
with benign prostatic hyperplasia (BPH) were included in
the study. Five age-matched healthy individuals served as
controls for specificity of cell capture and molecular anal-
ysis. Blood from apparently healthy volunteers was used
as a matrix for experiments in the model system
(described above) that tested samples containing known
amounts of cultured C4-2, LNCaP, and GFP-LNCaP cells.
Collection of blood specimens
Whole blood was collected by venipuncture into two 10
ml EDTA-containing Vacutainer®  tubes (BD, Franklin
Lakes, NJ) and stored on ice up to 4 hours before process-
ing. The collected blood was pooled and then processed
by immunocapture and plasma generation as described
in detail below. In cases when only one vacutainer tube
could be obtained, the processing procedure was: (1) per-
form immunomagnetic cell capture on 5 mL blood with
anti-EpCAM and anti-PSMA coated particles, (2) plasma
preparation from up to 4 mL blood, and (3) perform
immunomagnetic CTC isolation with anti-EpCAM
coated particles by using the remaining whole blood if
sufficient volume remained.
Immunomagnetic cell isolation of CTCs from whole blood 
specimens
Anti-EpCAM coated magnetic particles were purchased
from Invitrogen (Carlsbad, CA). Anti-PSMA coated par-
ticles were generated by reacting a monoclonal anti-
PSMA antibody (Beckman Coulter) with human anti-
mouse magnetic particles according to manufacturer's
specifications (Invitrogen, Carlsbad, CA).
For CTC isolation, 5 mL or 7.5 mL of whole blood was
incubated with 100 uL antibody-coated magnetic parti-
cles (anti-PSMA and/or anti-EpCAM) for 30 min at room
temperature. Magnetic-bound fractions were subjected
to three washing steps with phosphate buffered saline
(dPBS; Invitrogen) containing 0.2% (w/v) BSA (Jackson
Immuno Research, West Grove, PA) and subsequently
treated with Gen-Probe lysis buffer. The immunomagnet-
ically-enriched fractions were stored at - 20°C until
mRNA isolation was performed (see below).
Plasma processing
Blood specimens (up to 4 mL of EDTA-treated blood)
were subjected to sedimentation at 1,600 g for 10 min at
4°C to generate plasma. The plasma fraction was carefully
separated from the cellular fraction by standard labora-
tory pipetting with a 1 mL tip and mixed with an equal
volume of Gen-Probe lysis buffer. The treated plasma was
stored at -20°C until mRNA isolation was carried out (see
below).
Molecular Testing using TMA amplified assays
TMPRSS2 (T2):ERG gene fusion, PCA3 and PSA mRNAs
were either detected qualitatively or quantitatively using
assays that included the steps of magnetic target capture,
transcription-mediated amplification (TMA), and a
hybridization protection assay. Specifically, target mRNA
was purified from immunomagnetically enriched and
processed plasma fractions by hybridization to magnetic
particles via target-specific oligonucleotides (target cap-
ture step), amplified by TMA, and detected by using tar-
get-specific acridinium ester (AE)-labeled probes
(hybridization protection assay step) as described in [18].
Three T2:ERG splice variants were detected qualitatively,
T2:ERGa, b and c [28], also known as Types III, I and VI,
respectively [29]. Amplification primers for T2:ERG gene
fusion mRNA were located in T2 exon 1 and ERG exon 4
(T2:ERGa), T2 exon 1 and ERG exon 2 (T2:ERGb), and
T2 exons 1 and 2 and ERG exon 4 (T2:ERGc). The AE-
labeled probes for each T2:ERG splice variant spanned
the junction between T2 and ERG. Primers for PCA3
mRNA targeted exons 3 and 4, with the AE-labeled probe
spanning the exon 3/4 junction. Primers for PSA mRNA
targeted exons 2 and 3, with the AE-labeled probe span-
ning the exon 2/3 junction. PCA3 and PSA mRNAs were
detected quantitatively (signal-to-noise set to 2-fold or
greater), whereas T2:ERG was a qualitative assay (cutoff =
100,000 relative light units, RLUs). Calibrators and con-
trols consisted of T2:ERG, PCA3 or PSA in vitro tran-
scripts (IVTs) in detergent solution. The T2:ERGa, b and
c IVTs were prepared from plasmids provided by A.
Chinnaiyan (University of Michigan) [28]. IVT copy lev-
els were calculated based on spectroscopic concentration
determination using A260  measurements. Assays were
performed at Gen-Probe Incorporated using its DTS® 400
Systems and assay protocol for reagent addition volumesJost et al. Molecular Cancer 2010, 9:174
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and incubation times and temperatures as previously
described in [18].
Results
Model system studies for the detection of prostate cancer 
cells
We developed an immunomagnetic particle capture sys-
tem for the isolation of rare cells out of blood based on
antibody coated magnetic particles directed to epithelial
and prostate cell surface epitopes. To assess successful
isolation of cultured prostate cancer cells from a mixture
of normal blood cells, we used microscopic or molecular
methods.
GFP-expressing LNCaP cells were added to normal
donor blood and subsequently visualized before and after
immunomagnetic enrichment (Figure 1A, and Figure 1B,
C, respectively). As expected, the magnetic particle-
bound fraction contained fluorescent GFP-LNCaP cells
(Figure 1B) and only a small amount of non-fluorescent
structures, possibly representing non-specifically bound
blood cells (Figure 1C).
We next demonstrated molecular detection of prostate
cancer cells with Gen-Probe's protocol that includes tar-
get capture, TMA and hybridization protection assay
steps. PSA mRNA was detected in five C4-2 cells that had
been immunomagnetically enriched from 5 mL of normal
donor blood. The measured PSA mRNA copy numbers
correlated well with cellular input (Figure 1D).
To investigate the specificity of immunomagnetic cap-
ture, we mixed LNCaP cells with normal donor blood and
subjected the mixture to the enrichment steps using con-
trol magnetic particles that were devoid of anti-EpCAM
or anti-PSMA primary antibodies. No PSA mRNA was
detected in this condition, indicating that cell capture was
antibody dependent (Figure 1E). Moreover, PSA mRNA
was undetectable in magnetically enriched fractions from
normal blood donors that were devoid of added cultured
prostate cancer cells (Figure 1E). Both anti-EpCAM and
anti-PSMA coated magnetic particles gave equivalent
performance in these model system experiments (data
not shown).
PSA mRNA detection in CTC enriched fractions and plasma 
from prostate cancer patients
We next investigated the CTC enrichment method with
freshly drawn blood specimens from prostate cancer
patients. Samples were processed on site within four
hours from time of collection. For those specimens with
sufficient blood volume, we processed the specimens in
three fractions: (1) CTC enrichment using anti-EpCAM
plus anti-PSMA magnetic particles on whole blood; (2)
CTC enrichment using anti-EpCAM magnetic particles
alone on whole blood; and (3) plasma fraction using stan-
dard centrifugation. For specimens with insufficient
blood volume, we omitted the second fraction (anti-
EpCAM magnetic particles alone). Processed fractions
were then tested using amplified molecular assays.
Results for the PSA mRNA assay are summarized in
Figure 2. As shown in Figure 2A, the combined anti-
EpCAM plus anti-PSMA magnetic particle formulation
detected 9/16 androgen-independent (56%) and 3/17
androgen-dependent samples (18%). BPH and early stage
prostate cancer specimens were devoid of detectable PSA
mRNA (0/5 and 0/29, respectively). Results from
matched plasma fractions are shown in Figure 2B. In this
case, we detected 8/16 androgen-independent (50%) and
2/17 androgen-dependent specimens (12%). Positive
plasma fractions were in almost complete concordance
with CTC enriched fractions, although CTC enrichment
generally gave higher PSA mRNA copy numbers.
Figure 3 shows a comparison of PSA mRNA signals
from CTC enriched samples where sufficient blood vol-
ume had been collected from the patient to allow a com-
parison between the single antibody (anti-EpCAM) and
dual antibody (anti-EpCAM plus anti-PSMA) magnetic
particle formulations. The single antibody formulation
detected 8/14 cases (57%); whereas the dual antibody for-
mulation detected 7/14 cases (50%), with the majority of
positives from androgen-independent patients. We were
unable to measure any synergistic effect of the dual anti-
body magnetic bead formulation in this experiment (see
Discussion).
Comparison of three different molecular markers in CTC 
enriched fractions and plasma from prostate cancer 
patients
A comparison of PSA, PCA3 and TMPRSS2:ERG mRNA
signals is shown in Tables 1 and 2 for blood samples from
men with advanced prostate cancer that were processed
using the dual antibody magnetic particle formulation.
Results from men with androgen-dependent prostate
cancer are summarized in Table 1. These men all tested
negative for PCA3, whereas one of the men was positive
for TMPRSS2:ERG gene fusion mRNA. In contrast, more
of the men with androgen-independent prostate cancer
tested positive for all three markers (Table 2). PCA3 was
positive in 5/16 (31%) of these patients, although PCA3
mRNA copy numbers were at least one order of magni-
tude lower than PSA mRNA copy numbers in these
patients. Three of these patients tested positive for
TMPRSS2:ERG gene fusion mRNA in CTC enriched
samples (Table 2) and also in plasma (data not shown).
When any of the three markers were positive the detec-
tion rate increased to 63% (10/16 positive; Table 2). This
demonstrates feasibility of applying a research prototype
TMA-based molecular assay to CTC enriched patient
samples.Jost et al. Molecular Cancer 2010, 9:174
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Discussion
The present study was designed to assess the feasibility of
an immunomagnetic enrichment method for detecting
circulating prostate tumor cells using research prototype
TMA assays for prostate-specific mRNAs (PSA, PCA3
and the TMPRSS2:ERG gene fusion). Detection of PCA3
and/or TMPRSS2:ERG mRNA in whole blood could
potentially be used as a prognostic indicator of aggressive
prostate cancer. Enumeration of prostate CTCs alone
provides minimal information of the metastatic nature of
these cells, although the presence of CTCs in blood
w o u l d  n o t  b e  e x p e c t e d  i n  t h e  c a s e  o f  b e n i g n  d i s e a s e .
Indeed, an increasing number of studies have demon-
strated a correlation between prostate CTC numbers and
survival following surgical intervention [7,9,30].
Microfluidic cartridges have been described for enrich-
ing CTCs from whole blood with high efficiency [31].
These cartridges contained anti-EpCAM antibodies cou-
pled to spatially defined pillars in the device that were
shown to efficiently capture CTCs in model system
experiments. Interestingly, the authors of this study also
reported enumeration of CTCs in early stage prostate
cancer patients, with positive detection in about 90% of
cases investigated. Other studies also reported detection
of CTCs in early stage prostate cancer using anti-EpCAM
magnetic beads combined with PCR [32]. In contrast,
Figure 1 CTC enrichment in model system experiments. A) GFP-LNCaP cells mixed with blood from a normal donor were visualized by phase con-
trast and fluorescence microscopy using a 40× objective. Two fluorescent cells (see arrow) are visible in a background of non-fluorescent blood cells. 
B) GFP-LNCaP cell (see arrow) after enrichment with anti-EpCAM coated magnetic particles. Captured GFP-LNCaP cells were coated with numerous 
magnetic particles (non-fluorescent spheres, see arrowheads.) C) Immunomagnetic fraction from similarly processed normal donor blood (without 
added prostate cancer cells). This fraction is practically devoid of blood cells, with a low amount of non-fluorescent background material (see arrow). 
Magnetic particles are marked by arrowheads. D) PSA mRNA detection in immunomagnetically enriched C4-2 cells. Normal blood mixed individually 
in samples that contained 5, 10 and 25 added C4-2 cells were incubated and captured with anti-EpCAM magnetic particles out of 5 mL EDTA-treated 
blood. Error bars represent one standard deviation of repeat capture experiments (n = 10 for samples that contained 5 or 10 cells), n = 5 for samples 
that contained 25 cells). E) PSA mRNA copy numbers from immunomagnetically processed blood samples. Bars 1 through 8 represent replicate sam-
ples containing LNCaP cells (2 cells/mL, 4 mL total blood volume) that were processed using anti-EpCAM magnetic particles. Bars 9-12 represent con-
trol samples. The presence of LNCaP cells, control magnetic particles (devoid of anti-EpCAM primary antibody), or anti-EpCAM magnetic particles is 
indicated by the +/- symbols.
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CTC enumeration using the Veridex CellSearch™ System
failed to detect any CTCs in the blood of early stage pros-
tate cancer patients [33], whereas this system detected up
to 65% of patients with progressive, metastatic, castra-
tion-resistant disease [34].
PCA3 mRNA expression is elevated over 60-fold in
prostate cancer tissues compared to benign tissues [35].
PCA3 to PSA mRNA expression ratios are increased in
urine specimens from men with positive biopsy [18,36],
therefore it seemed reasonable to assume that similar
expression ratio differences could be used for molecular
Figure 2 PSA mRNA copy numbers in fractionated blood samples from prostate cancer patients. A) CTC enriched blood fractions processed 
using the dual antibody (anti-PSMA plus anti-EpCAM) magnetic particle formulation. B) Matched plasma fractions.
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subtyping of prostate CTCs in blood specimens. Unfortu-
nately, the positivity of the research prototype PCA3
assay used in these experiments was relatively low (less
than 30% of androgen-independent prostate cancer spec-
imens), and there were insufficient numbers of patient
samples for a clinical correlation.
TMPRSS2:ERG gene fusion mRNAs have been associ-
ated with aggressive prostate cancer morphology in tis-
sues [37] and a preliminary study using a combination of
TMPRSS2:ERG plus PCA3 assays has shown synergistic
diagnostic utility in urine specimens [19]. A preliminary
investigation of TMPRSS2:ERG mRNA transcript levels
in blood specimens of prostate cancer patients has been
reported [38]. Although the authors reported detection of
TMPRSS2:ERG gene fusions in 6/10 of the CTC enriched
samples by FISH analysis, TMPRSS2:ERG mRNA tran-
scripts could not be detected by RT-PCR. In contrast, the
TMA-based assay gave relatively high signals for
TMPRSS2:ERG mRNA in CTC enriched fractions from a
subset of men with advanced androgen-independent
prostate cancer. It should be noted that the prevalence of
TMPRSS2:ERG gene fusions in prostate cancer is 44-50%
in serum PSA-screened cohorts and 15-36% in popula-
tion-based cohorts [39,40]. In metastatic disease the
prevalence of TMPRSS2:ERG gene fusions was found to
be similar to that observed in organ-confined prostate
cancer [21,41]. In the present study, the prevalence of
TMPRSS2:ERG gene fusions was about 21% (3 out of 14
androgen-independent donors, see Table 2), which is
within the range of published studies [39,40].
As stated above, percentages of positive CTC detection
vary among published studies in advanced prostate can-
cer patients. It should be possible to improve detection
rates for PCA3 and TMPRSS2:ERG in CTC enriched
fractions by increasing the analytical sensitivity of these
assays. For example, the PCA3 assay used in the present
study was developed originally for urine specimens [18].
A more sensitive version of the assay is currently under
development for use with blood specimens. Positive
detection rates could also be improved by using larger
sample volumes. Regardless, the detection rates reported
here are encouraging and suggest that molecular stratifi-
cation of advanced prostate cancer patients is feasible.
Additional studies are needed to validate the utility of this
approach.
PSMA is known to be over-expressed in advanced pros-
tate cancer or castration resistant prostate cancer [14].
We were unable to measure a significant difference when
comparing anti-EpCAM magnetic beads versus our dual-
antibody magnetic beads. This was true for both andro-
gen-dependent and androgen-independent sub-popula-
tions (Figure 3). In one case, a patient was positive with
Figure 3 Comparison of matched CTC enriched blood fractions using either dual antibody (anti-PSMA plus anti-EpCAM) or single antibody 
(anti-EpCAM alone) magnetic particle formulations.
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the anti-EpCAM magnetic beads but not with the dual-
antibody magnetic beads. This could simply be a stochas-
tic difference when splitting a sample containing very
dilute numbers of CTCs. Clearly, larger numbers of
patient specimens would need to be tested for a signifi-
cant comparison.
The detection of prostate-specific mRNAs in patient
plasma is not a new finding, however it is interesting to
note that our results for plasma testing showed a high
correlation with results obtained when CTC enriched
fractions were tested, suggesting that patients who shed
high numbers of CTCs into blood have similarly high lev-
els of prostate-specific circulating mRNAs. Not surpris-
ingly, the CTC fraction exhibited higher copy numbers as
Table 1: Comparison of PSA, PCA3 and TMPRSS2:ERG 
mRNA copy levels in CTC enriched fractions from 
androgen-dependent prostate cancer patients.
Patient # PSA PCA3 TMPRSS2: ERG
1- - N / A
2- - N / A
3- - N / A
4 154,893 - -
5- - -
6- - -
7- - -
8- - -
9- - -
10 66 - -
11 1,928 - +
12 - - -
13 - - -
14 - - -
15 - - -
16 - - -
17 - - -
Blood samples from prostate cancer patients were processed 
using the dual antibody (anti-PSMA plus anti-EpCAM) magnetic 
particle formulation. CTC enriched fractions were prepared from 
patients diagnosed with advanced androgen-dependent 
prostate cancer (n = 17). N/A = insufficient sample available for 
measurement.
Table 2: Comparison of PSA, PCA3 and TMPRSS2:ERG 
mRNA copy levels in CTC enriched fractions from 
androgen-independent prostate cancer patients.
Patient # PSA PCA3 TMPRSS2: ERG
1 213,277 9,851 N/A
2- - N / A
36 3 1 - -
41 , 0 9 7 - -
5- 3 1 2 -
6- - -
76 5 8 - -
8 13,294 - +
9 189,634 546 -
10 10,088 4,478 -
11 208,727 - +
12 - - -
13 - - -
14 - - -
15 6,264 261 +
16 - - -
Blood samples from prostate cancer patients were processed 
using the dual antibody (anti-PSMA plus anti-EpCAM) magnetic 
particle formulation. CTC enriched fractions were prepared from 
patients diagnosed with advanced androgen-independent 
prostate cancer (n = 16). N/A = insufficient sample available for 
measurement.Jost et al. Molecular Cancer 2010, 9:174
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compared to the corresponding plasma fraction. In the
case of CTCs, 5-7.5 mL of whole blood was enriched and
tested, whereas a smaller volume of plasma was tested
without enrichment. Plasma samples are more accessible
and easier to work with than CTC enrichment from fresh
blood. This finding was also reported by Helo et al. using
other genetic markers [42], where plasma levels of KLK3,
KLK2, and PSCA mRNA showed a high correlation with
CTC numbers using the CellSearch™ assay. To our knowl-
edge, the present study is among the first to report a sim-
ilar correlation using amplified molecular assays for both
plasma and CTC enriched fractions, and suggests that
molecular subtyping of CTCs is feasible in advanced
prostate cancer patients.
The nature of circulating prostate-specific mRNAs is
worthy of further study. Recent studies suggest that they
could be encapsulated in circulating exosomes that are
s h e d  f r o m  i n v a s i v e  p r o s t a t e  t u m o r s  [ 4 3 ] .  I t  h a s  b e e n
hypothesized that this is one mechanism by which pros-
tate cancer cells can sensitize the immune system [44].
Further study of exosome fractions in prostate cancer
patients is warranted to determine whether this is a clini-
cally informative sample fraction.
In summary, a method for immunomagnetic enrich-
ment of prostate CTCs from patient whole blood speci-
mens has been described. This method is compatible
with automation, and is particularly compatible with
amplified assays based on TMA for detection of PSA,
PCA3, and TMPRSS2:ERG mRNAs. It also provides an
objective result without the use of cytometry or imaging.
The automated sample processing method is beneficial
for testing the large numbers of patient specimens that
would be needed for further clinical association studies.
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